The pharmacokinetics of orally administered butylscopolamine in greyhound dogs by Morris, Tim et al.
Pharmacokinetic Report 
The pharmacokinetics of orally administered butylscopolamine in greyhound dogs 
Short Title: pharmacokinetics of oral butylscopolamine in greyhounds 
Tim Morris1,3, Stuart W Paine1, Marjaana Viljanto2, Simon Hudson2,, Simon Gower3, Melissa 
Pittorino4 & Sally Colgan4 
1 School of Veterinary Medicine and Science, University of Nottingham, UK 
 2 LGC, Fordham UK 
3 Greyhound Board of Great Britain, London, UK  
4 Eurofins SCEC, Northbridge, Australia 
ABSTRACT 
The oral tablet formulation of butylscopolamine, which is available without prescription, is 
commonly used by trainers of racing greyhounds to treat functional urethral obstruction. As 
medication control of butylscopolamine is therefore required for such use to ensure the integrity of 
greyhound racing an administration study was performed in six greyhounds to determine the 
pharmacokinetics of orally administered butylscopolamine. A single dose of one 10 mg 
butylscopolamine tablet was administered orally to simulate this use in greyhound racing. Blood, 
urine and faeces were collected at regular intervals from the greyhounds for up to 9 days and 
butylscopolamine concentrations determined. There was some, but very limited, absorption of 
butylscopolamine, with rapid elimination from plasma with a mean half-life of 2 hours. Urine 
concentrations initially declined in a similar manner to the plasma pharmacokinetics but then 
entered a much longer half-life of approximately 50 hours. Faecal concentrations declined to very 
low levels between 48 and 120 hours. The use of orally administered butylscopolamine for 
functional urethral obstruction in greyhounds is unjustified due this very limited drug absorption. 
Medication control of butylscopolamine’s anti-spasmodic effect on the digestive tract is possible by 
setting screening limits based on the urinary and faecal drug levels as determined in this study. 
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INTRODUCTION Introduce the drug class and provide a very short summary of the clinical 
applications. 
Butylscopolamine is an antimuscarinic quaternary ammonium derivative of scopolamine used for 
relieving spasm of the smooth muscle of the digestive (Tytgat, 2007) and urinary systems 
(Papadopoulos et al 2014). It is available for medical and veterinary use in injectable formulations, 
both alone but also in combination with the non steroidal anti-inflammatory drug metamizole, and 
in tablet form, and is commonly referred to under its original trade name Buscopan®. 
Greyhound trainers commonly report that some racing greyhounds ‘tie up’ around racing, this being 
associated with excitement and characterised by full or partial inability to urinate. This condition 
has not been well defined (Van Meeuwen, 2009) but is likely to be a functional obstruction such as 
that defined as detrusor-urethral dyssynergia, with this considered to result from over discharge of 
acetylcholine to the urethral sphincter leading to contraction of the detrusor muscles (Espineira & 
Nickel, 1997, Tytgat, 2007). 
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Butylscopolamine is available as a tablet for oral administration for human medical use without 
prescription in the United Kingdom, Ireland and Australia, and related to this availability is 
commonly used by trainers symptomatically to treat full or partial inability to urinate in racing 
greyhounds.  
The aim of this study was characterise the analytical detection, the plasma and the urinary 
pharmacokinetics of butylscopolamine given orally to greyhound at the dose and formulation 
commonly used by trainers of racing greyhounds, assess systemic absorption of the drug, the 
clinical and animal welfare implications, and derive regulatory advice for greyhound racing. 
MATERIALS AND METHODS 
One 10mg tablet of butylscopolamine bromide (Buscopan® Boehringer Ingelheim) was 
administered orally on one occasion to six different greyhounds. Three female and three male 
animals were studied, with a mean dose of 0.31 mg/kg, a mean bodyweight of 32.9 kg and mean 
age of 4 years. Blood, urine and faecal samples were collected before drug administration.  Blood 
samples were collected after 1, 2 , 4, 6, 8, 12, 24, 36, 48, 96, 144 and 192 hours. Urine samples 
were collected after 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours. Faecal 
samples were collected at 12, 24, 48 , 120 , and 192 hours. The blood samples were heparinised and 
plasma obtained by centrifugation. All samples were stored at -20
o
C. Dogs were fed a commercial 
dry dog food (Dogpro PLUS Working Dog, Hypro Petcare P/L) with an additional portion of fresh 
meat, with the daily feed ration as two meals and had access to water at all times. The morning feed 
was not given on the treatment day prior to drug administration. The study was conducted in 
accordance to the principles of the VICH GCP guidelines (International Co-operation on 
Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products, Good 
Clinical Practice, June 2000, effective July 2001). Ethical approval was obtained from the New 
South Wales Department of Industry, Skills and Regional Development. The frozen samples were 
transported on dry ice to the analytical laboratory. 
Concentrations of butylscopolamine were measured in the pre- and post-administration 
plasma,urine and faecal samples. For extraction, ipratropium was selected as an internal marker due 
to its similar structure to butylscopolamine. For the urine (1 mL) and faecal samples (300 mg), 
ammonium bicarbonate (10 mM, pH10) was added and samples were centrifuged prior to solid 
phase extraction using cartridges (Isolute CBA 500 mg, Biotage EU). These were conditioned, the 
sample loaded, washed with ammonium bicarbonate and methanol and then eluted with 0.1% 
formic acid in methanol. For the plasma samples (200 µL), after addition of dichloromethane they 
were mixed and then centrifuged prior to transferring the organic layer to fresh tubes. Eluents were 
evaporated to dryness at ambient temperature, and reconstituted with methanol and water. 
Calibration and quality control samples were used in the range of 10-5,000 pg/mL for urine, 
200-50,000 pg/ml for faeces, and 50-20,000 pg/mL for plasma, and the methods were shown to be 
linear with correlation coefficients greater than 0.98 when weighting factor of 1/x was used. Faecal 
samples were diluted as required to allow quantification and the final concentration adjusted to 
express the amount in dry matter. 
The urine and plasma methods produced a lower limit of quantification (LLOQ) of 10 and 50 pg/
mL, respectively, and they were shown to be accurate and reproducible with acceptable inter-batch 
variability of precision and accuracy. The precision of the urine method was demonstrated to be 
within ±19.4% at LLOQ and within ±12.3% at higher QC concentrations (30, 2,500 and 4,500 pg/
mL), whilst the precision of the plasma method was within ±8.2% at all QC concentrations (50, 
100, 10,000 and 16,000 pg/mL). The accuracy of the urine method was within ±9.8% at all QC 
concentrations, whilst the accuracy of the plasma method was within ±13.0% at all QC 
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concentrations. Urine QC samples diluted 1-in-100 for urine samples also produced acceptable 
results with precision within ±5.6% and accuracy within ±8.2%.  
The LLOQ of faecal method was 0.2 ng/g. The precision of the method in a single batch was within 
±6.9% at QC concentrations of 0.2, 20 and 40 ng/g, whilst the accuracy was within ±11.9% at these 
QC concentrations.  
Sample analysis was performed by Aqcuity I-Class Ultra performance liquid chromatography 
(Waters UK) and Xevo TQ-S triple quadrupole mass spectrometry,Waters UK) in positive 
electrospray mode at a capillary voltage of 0.9 k, a source temperature of 150°C and a desolvation 
gas temperature at 500 °C. Selective reaction monitoring (SRM) was performed for 
butylscopolamine using the precursor ion of m/z 360.3 and the production ions of m/z 138.1 (for 
quantification), m/z 103.1, m/z 121.4 and m/z 194.2 (for qualification) at cone voltage of 30 V and 
collision energy of 22, 46, 26 and 20 eV, respectively. The SRM transition of 332.3 > 166.3 
(collision energy 22 eV, cone 3 V) was used for ipratropium.  
Chromatographic separation was achieved on an Acquity HSS T3 (100 mm x 2.1 mm, 1.8 µm) 
column using 0.1 % formic acid in methanol (A) and 0.1 % formic acid in water (B) as mobile 
phases. Gradient was operated at 50 ºC and at a flow rate of 0.4 mL/min. It was started at 10 % 
organic for 0.5 minutes followed by increase to 99.9 % A at 3 minutes. This was held for 1 minute 
before resuming the initial conditions and re-equilibrating.  
Pharmacokinetic parameters were estimated using non-compartmental analysis with Phoenix 
WinNonlin 7.0 (Pharsight Corporation, Cary, NC). The area under the plasma curve to infinity 
(AUC0-inf) was calculated using the log-linear trapezoidal rule with the AUC for the last time point

 to infinity determined from the final plasma concentration divided by the elimination rate constant 
for the terminal phase. 
RESULTS 
Following oral administration to six greyhounds of butylscoplamine bromide plasma 
pharmacokinetic parameters for are summarised in Table 1, mean plasma and urine concentrations 
of butylscopolamine are illustrated in Figure 1, and concentrations of butylscopolamine in faeces 
given in Table 2. 
DISCUSSION 
Greyhound trainers commonly use butylscopolamine tablets obtained without prescription when 
racing greyhounds ‘tie up’ around racing. The rationale for this use is questionable given the poor 
oral absorption of quaternary ammonium compounds (Leusch et al 2001; Tytgat, 2007) and reports 
of its limited efficacy in reducing urethral obstruction or pressure in dogs (Murakami et al 200; 
Papadopoulos et al 2014). No reported detection time studies for butylscopolamine in dogs have 
been found, and there is very limited pharmacokinetic data published, (Tytgat, 2007), in the 
veterinary product information, (Veterinary Medicines Directorate, 2011), or from other residue 
studies, (Committee For Veterinary Medicinal Products 1997).  
Butylscopolamine entering the duodenum, 10 mg in 500 mL of fluid, will lead to an approximate 
concentration of 20 micrograms per mL. If just 5% of butylscopolamine is absorbed then the initial 
concentration that the plexus will observe in the gut is approximately 1000 ng/mL. This value is 
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similar to the M3 receptor potency determined for guinea pig (Tytgat, 2007) and indicates an 
antispasmodic effect on the gut. However, 1000 ng/mL is massively higher than the peak plasma 
concentrations observed from this greyhound oral administration study which are in the low ng/mL 
range (Figure 1). The AUC0-∞ values are very low and lead to a very high oral clearance for 
butylscopolamine. The oral clearance is approximately 75 times greater than hepatic blood flow in 
the dog (approximately 40 mL/min/kg) suggesting a bioavailability of less than or equal to 1% 
(Gibaldi and Perrier, 1982). This study confirms the very low oral bioavailability observed for 
butylscopolamine in previous animal studies and no systemic anti-muscarinic effect. This, coupled 
with limited efficacy, would indicate its use for functional urethral obstruction such as that defined 
as detrusor-urethral dyssynergia, is unjustified. 
Butylscopolamine urine concentrations peak at 4 hours before initially declining in a similar manner 
to the plasma pharmacokinetics (Figure 1). The ratio of urine to plasma butylscopolamine 
concentrations between 4 hours (peak urine concentration) and 12 hours is very large with a value 
of approximately 1000. A very large ratio of this magnitude indicates that butylscopolamine 
undergoes rapid renal clearance that approaches renal blood flow in the dog. This seems likely as 
butylscopolamine is mainly excreted in the urine after parenteral administration (Committee For 
Veterinary Medicinal Products, 1997). Moreover, tiotropium (another quaternary ammonium drug) 
undergoes renal clearance that exceeds creatinine clearance indicating active secretion into the urine 
(Durham, 2004). After 2 days, the urine concentrations enter a much longer half-life of 
approximately 50 hours (Figure 1). It is not clear what is driving this long terminal phase in the 
urine but may be due to either some recirculation via the enterohepatic system or a small amount of 
the drug residing in a specific tissue leading to a large terminal volume of distribution.  Similar 
properties of other quaternary ammonium compounds suggests binding in tissues does occur 
(Leusch et al 2001). 
Medication control rules for animals in competitions rely either on an effect on body systems, a 
direct or indirect effect on performance, on relate the substance to its presence on a defined list. 
Medication control can be managed by the use of screening limits, based on an understanding of the 
levels of a drug that are no longer therapeutically effective (Morris 2015). This study also indicates 
that orally administered butylscopolamine could be a rational therapy for relieving spasm of the 
smooth muscle of the digestive tract. As such medication control is required for orally administered 
butylscopolamine in racing greyhounds, based on measures of blood or urinary concentrations. The 
total gastrointestinal tract transit time in dogs ranges from 22 to 57 hours (Boillat et al 2010). Faecal 
concentrations of butylscopolamine fall to ng/mL levels between 48 and 120 hours after oral 
administration (Table 2), and gut receptor potency (Tytgat, 2007) is a thousand times higher. This 
would indicate a urine screening level in the range of 100-10 pg/mL (Figure 1) should be the 
starting point for regulatory considerations to control the use of orally administered 
butylscopolamine in racing greyhounds. Such screening limits are set independently by regulatory 
authorities, guided by scientific information and analytical considerations (Morris 2015). 
It is concluded that the use of orally administered butylscopolamine for functional urethral 
obstruction in greyhounds is unjustified, and that medication control of its anti-spasmodic effect on 
the digestive tract will be possible by setting a urinary screening limit based on the urinary and 
faecal drug levels as determined in this study. 
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Figure 1. Mean, with standard deviation, plasma and urine concentrations in pg/mL of  
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Table 1: Plasma pharmacokinetic parameters for butylscopolamine following a single oral 10 mg 
dose to 6 greyhounds using a non-compartmental PK analysis. Cl/F represents the oral clearance of 
butylscopolamine and HL the half-life. * = Geometric mean 
Table 2. Concentrations of butylscopolamine in faeces, in ng/g dry matter, after following a single 
oral 10 mg dose to 6 greyhounds. SAT = Saturation of detection despite 1/1000 dilution, ND = Not 
Detected, 0.02 ng/mL is the Lower Limit of Quantification. Dogs are numbered in order of the time 











HL   
(hrs)
Dog 1 34.0 2136 2029 2.5
Dog 2 32.3 4650 1039 1.9
Dog 3 38.8 716 8608 1.6
Dog 4 33.5 1110 4506 3.2
Dog 5 31.5 6815 783 2.0
Dog 6 27.2 2013 2566 1.7
Mean 32.9 2907 3255 2.0*
Median 32.9 2075 2566 1.9
Hours after 
administration Dog 1 Dog 2 Dog 3 Dog 4 Dog 5= Dog 5=
0 ND 1.04 0.59 ND 2.04 ND
12 9.15 SAT 47.95 11255 SAT SAT
48 14.93 177.49 112.15 45.59 6.2 542.62
120 0.32 2.01 <0.02 0.22 0.38 1.84
196 0.62 0.2 ND 1.28 <0.02 0.6
